The NCI-MATCH clinical trial published in Clinical Cancer Research found that the drug combination trastuzumab-pertuzumab, approved for HER2-positive breast cancer, shrank tumors in patients with other cancers with high levels of the HER2 gene. NCI-MATCH is one of the largest precision oncology trials globally, offering potential treatment options for patients with advanced HER2-amplified cancers. While the study showed promise in certain patients, more refined patient selection or alternative treatment approaches may be needed for a larger proportion to benefit. This trial highlights the importance of identifying effective treatments with minimal side effects for patients with resistant cancers.
Source link
Cancer trial discovers a potentially broader role for an established dual HER2-blocking treatment
